4 The Guideline Development Group, National Collaborating Centre and NICE project team, and declarations of interests

4 The Guideline Development Group, National Collaborating Centre and NICE project team, and declarations of interests

4.1 Guideline Development Group

Pauline Bagnall
Uro-oncology Nurse Specialist, Northumbria Healthcare NHS Foundation Trust, North Shields

James Catto
Professor of Urology, University of Sheffield and Honorary Consultant Urological Surgeon, Sheffield Teaching Hospitals

Ashish Chandra
Consultant Uropathologist and Cytopathologist, Guy's and St Thomas' Hospital NHS Foundation Trust, London

Helen Chilcott
Macmillan Uro-oncology Clinical Nurse Specialist, North Bristol NHS Trust, Bristol

Ananya Choudhury
Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester

Robert Huddart
Reader in Urological Oncology and Honorary Consultant Clinical Oncologist, Institute of Cancer Research, Royal Marsden Hospital, London

Rob Jones
Reader and Honorary Consultant in Medical Oncology, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow

Phil Kelly
Patient and carer member

Antony Miller
Patient and carer member

Hugh Mostafid
Consultant Urologist, North Hampshire Hospital, Basingstoke

Jonathan Osborn
GP Partner, College Surgery Partnership, Cullompton, Devon

Marcus Ben Taylor
Consultant Radiologist, The Christie NHS Foundation Trust, Manchester

William Turner
Consultant Urologist, Cambridge University Hospitals NHS Foundation Trust

Julia Verne
Director, Director for Knowledge and Intelligence (South West), Public Health England, Bristol

Louise Warren
Patient and carer member (until June 2013)

4.2 National Collaborating Centre for Cancer

John Graham
Director

Andrew Champion
Centre Manager

Angela Bennett
Assistant Centre Manager

Lianne Gwillim
Project Manager

Jenny Stock
Project Manager

Kim Lewis
Project Manager

Nathan Bromham
Senior Researcher

Jennifer Hilgart
Researcher

Laura Bunting
Researcher

David Jarrom
Researcher

Elise Hasler
Information Specialist

Delyth Morris
Information Specialist

Matthew Prettyjohns
Senior Health Economist

4.3 NICE project team

Sharon Summers-Ma
Guideline Lead

Mark Baker
Clinical Adviser

Claire Ruiz
Guideline Commissioning Manager (until May 2013)

Katie Perryman Ford
Guideline Commissioning Manager (from May 2013)

Margaret Ghlaimi
Guideline Coordinator (until May 2014)

Jennifer Wells
Guideline Coordinator (until June 2014)

Joy Carvill
Guideline Coordinator (from July 2014)

Steven Barnes
Technical Lead

Jasdeep Hayre
Health Economist (until May 2014)

Paul Crosland
Health Economist (from July 2014)

Alison Lake
Editor (until December 2013)

Judy McBride
Editor (from January 2014)

4.4 Declarations of interests

The following members of the Guideline Development Group made declarations of interests. All other members of the Group stated that they had no interests to declare.

Member

Interest declared

Type of interest

Decision taken

Pauline Bagnall

Honorarium and travel to present on 'An overview and update on bladder cancer and management guidelines' for urology nurses. Funded by MSD.

Personal pecuniary; non‑specific

Declare and participate

James Catto

Received honorarium from GlaxoSmithKline regarding the use of dutasteride for prostate cancer.

Personal pecuniary; non‑specific

Declare and participate

James Catto

Received honorarium for attending the scientific advisory board of Orion Pharma regarding the development of an agent to treat prostate cancer.

Personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from GlaxoSmithKline for investigations of a novel therapeutic strategy in bladder cancer.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from European Union, framework 7 for prostate cancer, profiling and evaluation of ncRNA, ProspeR.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from Yorkshire Cancer Research for genetic instability and death in cancer cells.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from the Urological Foundation for investigation of microRNA mediated progression in urothelial cancer.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from Astellas for examination of the role of non‑coding RNA in the mediation of chemoresistance in bladder cancer.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from the urological foundation for an investigation of microRNA mediation progression in urothelial cancer.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from Yorkshire Cancer Research for epigenetic carcinogenesis in the urothelium, development of a model system and examination of candidate occupational carcinogens.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from the Urological Foundation for the loss of redundant mRNA export pathways in cancer cells, an investigation of this and novel therapeutic target and prognostic biomarker.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from the Wellcome Trust for the loss of redundant mRNA export pathways in cancer cells, an investigation of this and novel therapeutic target and prognostic biomarker.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received a research grant from Yorkshire Cancer Research for an investigation of the role of epigenetic silencing play in long non‑coding of RNA expression in bladder cancer.

Non‑personal pecuniary; non‑specific

Declare and participate

James Catto

Received an honorarium from Astellas for advisory board on enzalutamide for prostate cancer.

Personal pecuniary; non‑specific

Declare and participate

James Catto

Received reimbursement of travel expenses from the Royal College of Radiologist to attend the 1st Royal College of Radiologists' bladder cancer meeting in London and give a lecture on: 'Integrating biomarkers and imaging redesign management pathways – do we really need a transurethral resection in muscle invasive disease?'.

Personal pecuniary; non‑specific

Declare and participate

James Catto

Gave a lecture on updates in haematuria at the Urology and Men's Health Update in Sheffield.

Personal non‑pecuniary

Declare and participate

James Catto

Received reimbursement of travel expenses from European Association of Urology to attend the 14th Society of Urological Oncology annual meeting and give a lecture on the management of high‑grade non‑muscle‑ invasive bladder cancer.

Personal pecuniary: non‑specific

Declare and participate

Ashish Chandra

Presentation given on benign and malignant serous effusion cytology for the American Society of Cytopathology in November 2012.

Personal non‑pecuniary

Declare and participate

Ashish Chandra

Co‑author of pathology dataset for bladder cancer.

Personal non‑pecuniary

Declare and participate

Ashish Chandra

Collaborator providing pathology input for the correlation of distribution of tumour in the prostate‑based histoscanning and comparing results on template biopsy and radical prostatectomy specimens. Funded by King's College London.

Non‑personal pecuniary; non‑specific

Declare and participate

Ashish Chandra

Collaborator providing pathology input for the Trans‑Atlantic Prostate Group studies using tissue microarrays of prostate tissue collected retrospectively from a cohort of UK patients. Funded by King's College London.

Non‑personal pecuniary; non‑specific

Declare and participate

Ashish Chandra

Collaborator providing pathology input for evaluating the role of TMPRSS2‑ERG antibody in predicting hormone sensitivity of prostate cancer and supervisor of the MSc project. Funded by King's College London.

Non‑personal pecuniary; non‑specific

Declare and participate

Ashish Chandra

Collaborator providing pathology input for a collaboration with Harvard University to explore the role of lipid metabolism in prostate cancer tissue microarrays from UK patients. Funded by King's College London.

Non‑personal pecuniary; non‑specific

Declare and participate

Ashish Chandra

Received expenses from Abbott for attending an advisory board looking at bladder and prostate cancer testing.

Personal pecuniary; non‑specific

Declare and participate

Helen Chilcott

Honorarium received for a talk entitled 'Prostate cancer – long‑term condition and survivorship' for GPs. Paid for by AstraZeneca.

Non‑specific

Declare and participate

Ananya Choudhury

Received honorarium from Janssen for giving a lecture on prostate cancer in September 2011.

Personal pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Received reimbursement of travel expenses from Cancer Research UK for attendance at an NCRI bladder clinical studies group meeting in November 2011.

Personal pecuniary; specific

Declare and participate

Ananya Choudhury

Received reimbursement of travel expenses from Cancer Research UK for attendance at an NCRI bladder clinical studies group meeting in November 2012.

Personal pecuniary; specific

Declare and participate

Ananya Choudhury

Received reimbursement of travel expenses from Cancer Research UK for attendance at a CT‑Rad studies group meeting in November 2011.

Personal pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Received reimbursement of travel expenses from Cancer Research UK for attendance at a CT‑Rad studies group meeting in June 2012.

Personal pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Received honorarium from Pierre Fabre for attending a discussion group on metastatic bladder cancer in August 2012.

Personal pecuniary; specific

Declare and withdraw from discussion on topics regarding metastatic bladder cancer until August 2013

Ananya Choudhury

Principal investigator on the Mainsail trial to evaluate the safety and effectiveness of lenalidomide in combination with docetaxel and prednisone for patients with castrate‑resistant prostate cancer. Not involved in trial protocol and is funded by Celgene Corporation.

Non‑personal pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Principal investigator on the AFFIRM trial to evaluate the safety and efficacy of MDV3100 in patients with castrate‑resistant prostate cancer, who have previously been treated with docetaxel‑based chemotherapy. Not involved in trial protocol and is funded by Medivation Inc.

Non‑personal pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Chief investigator and involved in the trial protocol of the trial of the measurement of gemcitabine metabolites in blood and urine as predictors of response to GemX bladder radiotherapy. Funded by Christie Charitable Funds.

Non‑personal pecuniary; specific

Declare and participate

Ananya Choudhury

Chief investigator and involved in the trial protocol of the trial of the simultaneous cone beam computed tomography (CBCT) acquisition during Arc radiotherapy in prostate cancer. Funded by Christie Charitable Funds.

Non‑personal pecuniary; specific

Declare and participate

Ananya Choudhury

Chief investigator and involved in the trial protocol of the trial on MRE11 as an outcome prediction biomarker in bladder cancer radiotherapy (MOBIBLART). Funded by Christie Charitable Funds.

Personal pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Chief investigator and involved in the trial protocol of a phase I feasibility study to compare early response assessment and planning volumes with contract‑enhanced computer tomography (CT), MRI including diffusion weighted MRI (DWI) and dynamic‑contrast enhanced (DCE) MRI in patients with limb sarcoma undergoing pre‑operative radiotherapy. Funded by Christie Charitable Funds.

Non‑personal pecuniary; specific

Declare and participate

Ananya Choudhury

Chief investigator for a study looking at the role of rectal balloons in prostate radiotherapy (BRAD). Funded by Men Matter Charity.

Non‑personal pecuniary; specific

Declare and participate

Ananya Choudhury

Member of the NCRI bladder clinical studies group.

Personal non‑pecuniary

Declare and participate

Ananya Choudhury

Member of the CT‑Rad group.

Personal non‑pecuniary

Declare and participate

Ananya Choudhury

Member of the British Uro‑Oncology Group.

Personal non‑pecuniary

Declare and participate

Ananya Choudhury

Member of the European Society of Therapeutic Radiation Oncology.

Personal non‑pecuniary

Declare and participate

Ananya Choudhury

Author on publication in the journal Radiotherapy Oncology. Entitled: 'Necrosis predicts benefit from hypoxia‑modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial'.

Personal non‑pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Author of a chapter in a book ('Treatment of bladder cancer') entitled: 'Bladder‑sparing strategies for invasive bladder cancer'.

Personal non‑pecuniary; specific

Declare and participate

Ananya Choudhury

Reviewed patient information on management of bladder cancer for NHS Choices.

Personal non‑pecuniary; non‑specific

Declare and participate

Ananya Choudhury

Travel, accommodation and registration to attend ESTRO (European radiotherapy) in Amsterdam. Funding from Janssen.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Received an honorarium from Stratagem for attending an advisory board on the treatment of radiation cystitis.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Received payment for management of bladder cancer education session from Pierre Fabre.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Received an honorarium from MA Healthcare Ltd for giving a case presentation on the management of bladder cancer patients at a renal and bladder conference.

Personal pecuniary; specific

Declare and participate

Robert Huddart

Received subsistence expenses from Janssen for attending a conference on abiraterone for prostate cancer.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Chief investigator, and involved in designing the trial protocol of BC2001 trial, a randomised phase III study of radiotherapy with and without synchronous chemotherapy in muscle‑invasive bladder cancer. Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator and involved in designing the trial protocol of SPARE trial, a randomised selective bladder preservation against radical excision in muscle invasive transitional cell carcinoma of the bladder. Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator and involved in designing the trial protocol of IDEAL trial for image guided dose escalated adaptive bladder radiotherapy. Funded by Cancer Research UK and the Royal College of Radiologists.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator, and involved in designing the trial protocol for hypofractionated radiotherapy in bladder cancer, funded by NIHR.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator, and involved in designing the trial protocol for IMRT for bladder cancer, funded by NIHR.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Co‑investigator, involved in developing trial protocol, the application for funding and on trial management group of BOXIT trial, for the standard treatment with or without celecoxib for transitional cell bladder cancer. Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Co‑investigator, involved in trial application of ToTem study, a phase I/II single‑arm trial to evaluate the combination of cisplatin and gemcitabine with the mTOR inhibitor temsirolimus for first‑line treatment of patients with advanced transitional cell carcinoma of the urothelium. Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Principal investigator for SUCCINCT trial looking at the addition of sunitinib to standard 2‑drug cisplatin/gemcitabine chemotherapy for first‑line treatment of patients with advanced bladder cancer. Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Local principal investigator for TOUCAN, a randomised phase II trial of carboplatin and gemcitabine ± vandetanib in first‑line treatment of advanced urothelial cancer in patients who are not suitable to receive cisplatin. Funded by Cancer Research UK and AstraZeneca.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Local principal investigator for LAMB, a phase II/III randomised 2‑arm trial comparison of maintenance lapatinib versus placebo after first‑line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer. Funded by Cancer Research UK and AstraZeneca.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Local principal investigator for POUT, a peri‑operative chemotherapy or surveillance in upper tract urothelial cancer trial. Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator of Cancer Research UK TE22 and TE23 national testicular genetic genome wide association study.

Non‑personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Co‑investigator of TRIST trial of seminoma surveillance.

Non‑personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Co‑investigator of GEM‑TIP trial of salvage testis chemotherapy.

Non‑personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Co‑investigator of 111 study of adjuvant chemotherapy in NSGCT.

Non‑personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Co‑investigator of TRYMS trial of hormone replacement in cancer survivors.

Non‑personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Member/trustee of British Uro‑oncology Group.

Personal non‑pecuniary

Declare and participate

Robert Huddart

Published research articles relating to bladder cancer treatment, specifically a trial that showed to improve outcome for chemo‑radiotherapy over radiotherapy and has publicly stated that this should be the standard of care.

Personal non‑pecuniary

Declare and participate

Robert Huddart

Member of the NCRI bladder cancer studies group.

Personal non‑pecuniary

Declare and participate

Robert Huddart

Member of the NCIN urology site‑specific clinical reference group, representing testis.

Personal non‑pecuniary

Declare and participate

Robert Huddart

Presentation at NCRI urology meeting on the BC2001 trial (no payment or expenses received).

Personal non‑pecuniary; specific

Declare and participate

Robert Huddart

Travel expenses for a presentation on 'How should IMRT and IGRT be used in bladder radiotherapy' at a bladder cancer meeting hosted by The Royal College of Radiologists.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Travel expenses for a presentation on 'Advances in the non‑surgical management of bladder cancer' at a conference hosted by the Royal College of Radiologists.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Invited to be a local site principal investigator for a new neo‑adjuvant chemotherapy trial funded by NCRI (no remuneration).

Personal non‑pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator of RAIDER trial (A randomised phase II trial of adaptive image‑guided, standard or dose‑escalated tumour boost radiotherapy in the treatment of transitional cell carcinoma of the bladder). Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Chief investigator of HYBRID trial (A multicentre randomised phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning in patients with muscle invasive bladder cancer). Funded by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and participate

Robert Huddart

Received reimbursement of travel expenses from Janssen Pharmaceuticals to attend ASCO in June 2014.

Personal pecuniary; non‑specific

Declare and participate

Robert Huddart

Invited to speak on bladder cancer radiotherapy at the East Anglian bladder meeting in October 2014. No fee received.

Personal non‑pecuniary

Declare and participate

Robert Huddart

Spoke on bladder cancer image‑guided radiotherapy at Royal College of Radiologists' meetings in April and June 2014. No fee received.

Personal non‑pecuniary

Declare and participate

Robert Huddart

Has been invited to talk on the RAIDER trial at the Australian Radiotherapy/Cancer meeting in September 2014. Will be receiving reimbursement of travel expenses and an honorarium from AstraZeneca.

Personal pecuniary

Declare and withdraw from discussion of any topics that involve interventions manufactured by Astra Zeneca

Rob Jones

Received an honorarium from Janssen for a consultancy on prostate cancer in November 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Janssen for speaking on prostate cancer in September 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Pfizer for a consultancy on renal cancer in November 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Pfizer for speaking on renal cancer in June 2011.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Pfizer for speaking on renal cancer in October 2011.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Pfizer for speaking on renal cancer in November 2011.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Novartis for a consultancy on renal cancer in August 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Sanofi‑Aventis for a consultancy on prostate cancer in November 2011.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Sanofi‑Aventis for a consultancy on prostate cancer in July 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Sanofi‑Aventis for speaking on prostate cancer in October 2011.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from GlaxoSmithKline for speaking on renal cancer in June 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from GlaxoSmithKline for speaking on renal cancer in November 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Astellas for a consultancy on renal cancer in March 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from AstraZeneca for a consultancy on the development of a non‑marketed product in prostate cancer in January 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from AstraZeneca for a consultancy on prostate cancer in January 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from CureVac for a consultancy on prostate cancer in November 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Roche for a consultancy on access to medicines in Scotland.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received reimbursement of travel expenses from GlaxoSmithKline for attending ASCO, which covered all aspects of medical treatment of cancer in May 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received reimbursement of travel expenses from GlaxoSmithKline for attending ESMO, which covered all aspects of medical treatment of cancer in October 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Dendreon for a consultancy on prostate cancer in November 2012.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Director of CRUK‑CTU, which coordinates PLUTO trial.

Personal pecuniary; non‑specific

Declare and withdraw from topics covering pazopanib versus weekly paclitaxel in relapsed or progressive TCC of urothelium in bladder cancer

Rob Jones

Director of Beatson Clinical Trials unit, which conducts trials for pharmaceutical and biotech companies, none relevant to bladder cancer in the past 12 months.

Non‑personal pecuniary; non‑specific

Declare and participate

Rob Jones

Chief investigator and involved in trials protocol on PLUTO trial, a randomised phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive TCC of urothelium in bladder cancer. Part sponsored by GlaxoSmithKline and coordinated by Cancer Research UK.

Non‑personal pecuniary; specific

Declare and withdraw from topics covering pazopanib versus weekly paclitaxel in relapsed or progressive TCC of urothelium in bladder cancer

Rob Jones

Local principal investigator for the LAMB trial, for lapatinib for people with bladder cancer, which has spread, and is a member of the trial management group. Part funded by GlaxoSmithKline.

Non‑personal pecuniary; specific

Declare and participate

Rob Jones

Chief investigator and involved in trial protocol for TOUCAN trial, carboplatin, gemcitabine and vandetanib to treat TCC that has spread. Funded by AstraZeneca.

Non‑personal pecuniary; specific

Declare and withdraw from topics covering carboplatin, gemcitabine and vandetanib

Rob Jones

Chief investigator for MAdCap, for prostate cancer, funded by Roche.

Non‑personal pecuniary; non‑specific

Declare and participate

Rob Jones

Chief investigator for ASPEN, for renal cancer, funded by Novartis and Pfizer.

Non‑personal pecuniary; non‑specific

Declare and participate

Rob Jones

Presented data on bladder cancer for a study funded by Topotargets.

Non‑personal pecuniary; specific

Declare and participate

Rob Jones

Principal investigator on TOTEM trial to evaluate the addition of temsirolimus to the standard of 2‑drug cisplatin/gemcitabine chemotherapy for first‑line treatment of patients with advanced bladder cancer.

Non‑personal pecuniary; specific

Declare and withdraw from discussions on any topic regarding cisplatin/gemcitabine for first‑line treatment of patients with advanced bladder cancer (Chair decision that he can be asked questions)

Rob Jones

Principal investigator on SUCCINCT trial to evaluate the addition of sunitinib to standard 2‑drug cisplatin/gemcitabine chemotherapy for first‑line treatment of patients with advanced bladder cancer.

Non‑personal pecuniary; specific

Declare and withdraw from topics covering cisplatin/gemcitabine chemotherapy for first‑line treatment of bladder cancer

Rob Jones

Principal investigator on trials not relating to bladder cancer. Trials funded by Active Biotech research, Millennium/Takeda, Novartis, Pfizer, Sanofi‑Aventis.

Non‑personal pecuniary; non‑specific

Declare and participate

Rob Jones

On the editorial committee for the renal cancer clarity newsletter produced by the James Whale Fund.

Personal non‑pecuniary

Declare and participate

Rob Jones

Reviews patient information leaflets and speaks at education meeting for Prostate Cancer UK, no payments are received.

Personal non‑pecuniary

Declare and participate

Rob Jones

Received an honorarium from Exelixis for consultancy advice on an emerging drug in bladder cancer.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Astellas for consultancy on prostate cancer.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received an honorarium from Bayer for consultancy advice on the use of sorafenib in renal cell carcinoma.

Personal pecuniary; non‑specific

Declare and participate

Rob Jones

Received payment from Bristol‑Myers Squibb for consultancy regarding immunotherapy in renal cancer.

Personal pecuniary; non‑specific

Declare and participate

Phil Kelly

Lay member of the NICE Safe Staffing Advisory Committee that developed the NICE guideline 'Safe staffing for nursing in adult inpatient wards in acute hospitals'. Attendance fee and expenses.

Personal pecuniary; non‑specific

Declare and participate

Hugh Mostafid

Agreement with Kyowa to provide occasional advice on issues regarding intravesical chemotherapy. Agreement was formally terminated in February 2012.

Personal pecuniary; specific

Declare and withdraw from discussions on intravesical chemotherapy until February 2013

Hugh Mostafid

Wife works on an ad‑hoc basis as a marketing consultant for pharmaceutical company marketing new preparation of mitomycin.

Personal family interest; specific

Declare and withdraw from discussion on all topics regarding intravesical chemotherapy.

20 August 2013: This interest is no longer applicable as wife did not take up job

Hugh Mostafid

Part of the trial management group for an NIHR‑funded trial on standard treatment with or without celecoxib for transitional cell bladder cancer (BOXIT).

Non‑personal pecuniary; specific

Declare and participate

Hugh Mostafid

Co‑applicant on the trial management group for an NIHR‑funded trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment or other standard treatment for bladder cancer.

Non‑personal pecuniary; specific

Declare and participate

Hugh Mostafid

Chief investigator, involved in developing the trial protocol on a NIHR‑funded trial for standard surgical management of patients with low‑risk bladder cancer versus intravesical chemotherapy.

Non‑personal pecuniary; specific

Declare and participate

Hugh Mostafid

Member of the NCRI bladder cancer clinical trials study group.

Personal non‑pecuniary

Declare and participate

Hugh Mostafid

Founder member and trustee of Action on Bladder Cancer, administrative role and patient education.

Personal non‑pecuniary

Declare and participate

Hugh Mostafid

Co‑author of South West Surrey and Hampshire Cancer Network guidelines on bladder cancer.

Personal non‑pecuniary

Declare and participate

Jonathan Osborn

Director of Russell Osborn management company.

Personal pecuniary; non‑specific

Declare and participate

Jonathan Osborn

Director of Vosper International Ltd, ship design company.

Personal pecuniary; non‑specific

Declare and participate

Marcus Ben Taylor

Received honorarium in November 2011 from Novartis for lecture on recent advances and current strategies in GISTs.

Personal pecuniary; non‑specific

Declare and participate

Marcus Ben Taylor

Chief investigator, involved in developing trial protocol for a study of Buscopan to improve image quality in pelvic MRI. Funded by Christie Charitable Funds.

Non‑personal pecuniary; non‑specific

Declare and participate

Marcus Ben Taylor

Chief investigator, involved in developing trial protocol for a study on diffusion‑weighted imaging in pelvic MRI. Funded by radiology department, The Christie.

Non‑personal pecuniary; non‑specific

Declare and participate

Marcus Ben Taylor

Member of the Royal College of Radiologists' Guideline Group, involved in writing guideline for imaging of lymphoma.

Personal non‑pecuniary

Declare and participate

Marcus Ben Taylor

Member of the NCAT reference group for peer review measures on carcinoma of unknown primary.

Personal non‑pecuniary

Declare and participate

William Turner

Project group member of Addenbrooke's Urology patient information project (AUPIP) trying to improve shared and informed decision‑making.

Personal non‑pecuniary; non‑specific

Declare and participate

William Turner

Lead of medical advisory group on bladder cancer in the NHS right care programme. The decision aid is being developed by Totally Health.

Personal non‑pecuniary; non‑specific

Declare and participate

  • National Institute for Health and Care Excellence (NICE)